EUVIMEDEUVIMED entdecken
Crossref

Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms

Marie-Charlotte Bourrienne, Stéphane Loyau, Dorothée Faille, Juliette Gay, Séléna Akhenak, Carine Farkh, Véronique Ollivier, Mialitiana Solonomenjanahary, Sébastien Dupont, Christine Choqueux, Jean-Luc Villeval, Isabelle Plo und 4 weitere

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.07.031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Marie-Charlotte Bourrienne und 15 weiteren Autor:innen. Beteiligte Einrichtung: Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM U1144, Université Paris Cité, Paris, France; Laboratoire Hématologie, AP-HP, Hôpital B…. Hauptthemen laut MEDLINE: Janus Kinase 2, Fibrinolysis, Myeloproliferative Disorders, Tissue Plasminogen Activator. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Institut National de la Santé et de la Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Myeloproliferative neoplasms (MPNs) are characterized by a high rate of thrombotic complications that contribute to morbidity and mortality. MPN-related thrombogenesis is assumed to be multifactorial, involving both procoagulant and proinflammatory processes. Whether impaired fibrinolysis also participates in the prothrombotic phenotype of MPN has been poorly investigated. OBJECTIVES: We determined whether MPN, particularly JAK2V617F-positive MPN, is associated with fibrinolytic changes. METHODS: Tissue-type plasminogen activator (tPA)-mediated fibrinolysis was evaluated both in whole blood and plasma from mice with a hematopoietic-restricted Jak2V617F expression compared with wild-type (WT) mice (Jak2WT) using (1) halo clot lysis, (2) front lysis, and (3) plasmin generation assays. tPA clot lysis assay was performed in the plasma from 65 MPN patients (JAK2V617F mutation, n = 50; CALR mutations, n = 9) compared with 28 healthy controls. RESULTS: In whole blood from Jak2V617F mice, we observed a decreased fibrinolysis characterized by a significantly lower halo clot lysis rate compared with Jak2WT (95 ± 22 vs 147 ± 39 AU/min; P < .05). Similar results were observed in plasma (halo clot lysis rate, 130 ± 27 vs 186 ± 29 AU/min; front lysis rate, 2.8 ± 1.6 vs 6.1 ± 1.2 μm.min-1; P < .05). Plasmin generation was significantly decreased both in plasma clots and standardized fibrin clots from Jak2V617F mice compared with Jak2WT mice. Among MPN patients, impaired tPA-related fibrinolysis with prolonged clot lysis time was observed in JAK2V617F and CALR patients. Plasminogen activator inhibitor-1 and α2-antiplasmin were significantly increased in plasma from JAK2V617F patients compared with controls. CONCLUSION: Our results suggest that impaired tPA-mediated fibrinolysis represents an important prothrombotic mechanism in MPN patients that requires confirmation in larger studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2FibrinolysisMyeloproliferative DisordersTissue Plasminogen ActivatorAnimalsHumansThrombosisMutationMaleFibrinolysinFemaleMiceMiddle AgedMice, Inbred C57BLCase-Control StudiesCalreticulinAgedPhenotypeMice, TransgenicBlood Coagulation

Stichwörter der Autor:innen

JAK2 proteinfibrin clot lysis timefibrinolysismyeloproliferative disorders

Substanzen

Janus Kinase 2JAK2 protein, humanTissue Plasminogen ActivatorJak2 protein, mouseFibrinolysinCalreticulin

Autor:innen und Institutionen

  • Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM U1144, Université Paris Cité, Paris, France; Laboratoire Hématologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France. Electronic address: marie-charlot…
  • Université Paris Cité and Université Sorbonne Paris Nord, INSERM, LVTS, Paris, France.
  • Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM U1144, Université Paris Cité, Paris, France; Laboratoire Hématologie, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France.
  • Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM U1144, Université Paris Cité, Paris, France.
  • INSERM U1287, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Optimisation Thérapeutique en Neuropsychopharmacologie, INSERM U1144, Université Paris Cité, Paris, France; Département de Neurologie, AP-HP, Hôpital Lariboisière, FHU NeuroVasc, Paris, France.

Förderung

  • Institut National de la Santé et de la Recherche Médicale

Zitieren

APA

Bourrienne, M. C., Loyau, S., Faille, D., Gay, J., Akhenak, S., Farkh, C., Ollivier, V., Solonomenjanahary, M., Dupont, S., Choqueux, C., Villeval, J. L., Plo, I., Edmond, V., Ho-Tin-Noé, B., Ajzenberg, N., & Mazighi, M. (2024). Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.07.031

Vancouver

Bourrienne MC, Loyau S, Faille D, Gay J, Akhenak S, Farkh C, et al. Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.07.031

BibTeX
@article{Bourrienne2024,
  author = {Bourrienne, Marie-Charlotte and Loyau, Stéphane and Faille, Dorothée and Gay, Juliette and Akhenak, Séléna and Farkh, Carine and Ollivier, Véronique and Solonomenjanahary, Mialitiana and Dupont, Sébastien and Choqueux, Christine and Villeval, Jean-Luc and Plo, Isabelle and Edmond, Valérie and Ho-Tin-Noé, Benoît and Ajzenberg, Nadine and Mazighi, Mikaël},
  title = {Impaired fibrinolysis in JAK2V617F-related myeloproliferative neoplasms},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.07.031}
}
Kostenlos starten →